Caitlin Taylor, MD
Hematology & Oncology · New Orleans, LANPI 1528422987
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,240 of the $4,750 with a category attached, or 68.2%. AstraZeneca accounts for 83.5% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $3,975, more than ten times the $13 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 30 payments — averaging $158.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Merck$288
- Myriad Genetic Laboratories, Inc.$147
- Tempus AI, Inc$136
- Beigene USA, Inc.$40
- Beone Medicines USA, Inc.$40
- plus $133 from 5 others
Across 2 payments — averaging $27,856 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$56K
What the payments were for
- Speaking & faculty fees$3,24068%
- Food & beverage$1,47731%
- Education$331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $3,965 |
| Merck | 4 | $288 |
| Myriad Genetic Laboratories, Inc. | 3 | $147 |
| Tempus AI, Inc | 2 | $136 |
| Beigene USA, Inc. | 2 | $40 |
| Beone Medicines USA, Inc. | 2 | $40 |
| Genentech, Inc. | 1 | $36 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $30 |
| Solventum Corporation | 1 | $25 |
| Dilon Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,750 in reported general payments places this provider in the 50th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 45 | $660,827 |
| KisqaliRibociclib Succinate | 21 | $343,989 |
| VeozahFezolinetant | 16 | $8,868 |
| Anastrozole | 307 | $4,925 |
| Tamoxifen Citrate | 64 | $1,312 |
| Dexamethasone | 21 | $230 |
| Ondansetron Hcl | 22 | $192 |
| Gabapentin | 25 | $188 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $163 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $139 |
| Prochlorperazine Maleate | 19 | $127 |
| Olanzapine | 21 | $85 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.